Myositis Specific Autoantibodies: A Clinical Perspective

References

• Bailey EE, Fiorentino DF. Amyopathic dermatomyositis: definitions, diagnosis, and management. Curr Rheumatol Rep. 2014;16(12):465.25366932
   PubMed Web of Science ®Google Scholar
• Marvi U, Chung L, Fiorentino DF. Clinical presentation and evaluation of dermatomyositis. Indian J Dermatol. 2012;57(5):375.23112358
   PubMedGoogle Scholar
• Mammen AL. Dermatomyositis and polymyositis: clinical presentation, autoantibodies, and pathogenesis. Ann N Y Acad Sci. 2010;1184:134–153. doi:10.1111/j.1749-6632.2009.05119.x20146695
   PubMed Web of Science ®Google Scholar
• Findlay AR, Goyal NA, Mozaffar T. An overview of polymyositis and dermatomyositis. Muscle Nerve. 2015;51:638–656. doi:10.1002/mus.2456625641317
   PubMed Web of Science ®Google Scholar
• Strowd LC, Jorizzo JL. Review of dermatomyositis: establishing the diagnosis and treatment algorithm. J Dermatolog Treat. 2013;24:418–421. doi:10.3109/09546634.2012.69754022686682
   PubMed Web of Science ®Google Scholar
• Malik A, Hayat G, Kalia JS, Guzman MA. Idiopathic inflammatory myopathies: clinical approach and management. Front Neurol. 2016. doi:10.3389/fneur.2016.00064
   Web of Science ®Google Scholar
• Marc M Diagnosis and differential diagnosis of dermatomyositis and polymyositis in adults; 2019 Available from: https://www.uptodate.com/contents/diagnosis-and-differential-diagnosis-of-dermatomyositis-and-polymyositis-in-adults.Accessed 1216, 2019.
   Google Scholar
• Wolstencroft PW, Fiorentino DF. Dermatomyositis clinical and pathological phenotypes associated with myositis-specific autoantibodies. Curr Rheumatol Rep. 2018;20(5):28.29637414
   PubMed Web of Science ®Google Scholar
• Hamaguchi Y, Fujimoto M, Matsushita T, et al. Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome. PLoS ONE. 2013;8;e60442.23573256
   PubMed Web of Science ®Google Scholar
• Ghirardello A, Borella E, Beggio M, Franceschini F, Fredi M, Doria A. Myositis autoantibodies and clinical phenotypes. Auto Immun Highlights. 2014;5:69–75. doi:10.1007/s13317-014-0060-426000158
   PubMedGoogle Scholar
• Nishikai M, Ito M. Autoantibodies in polymyositis and dermatomyositis. IRYO - Japanese J Natl Med Serv. 1981;35:123–128.
   Google Scholar
• Fujimoto M, Watanabe R, Ishitsuka Y, Okiyama N. Recent advances in dermatomyositis-specific autoantibodies. Curr Opin Rheumatol. 2016;28:636–644. doi:10.1097/BOR.000000000000032927533321
   PubMed Web of Science ®Google Scholar
• McHugh NJ, Tansley SL. Autoantibodies in myositis. Nat Rev Rheumatol. 2018;14(5):290.29674612
   PubMed Web of Science ®Google Scholar
• Grossman C, Lidar M. Myositis autoantibodies In: Autoantibodies. Third ed; publisher Elsevier BV. 2013;72:613–616.
   Google Scholar
• Palterer B, Vitiello G, Carraresi A, Giudizi MG, Cammelli D, Parronchi P. Bench to bedside review of myositis autoantibodies. Clin Mol Allergy. 2018;16. doi:10.1186/s12948-018-0084-9
   Google Scholar
• Femia AN, Vleugels RA, Callen JP. Cutaneous dermatomyositis: an updated review of treatment options and internal associations. Am J Clin Dermatol. 2013;14:291–313. doi:10.1007/s40257-013-0028-623754636
   PubMed Web of Science ®Google Scholar
• Burd CJ, Kinyamu HK, Miller FW, Archer TK. UV radiation regulates Mi-2 through protein translation and stability. J Biol Chem. 2008;283:34976–34982. doi:10.1074/jbc.M80538320018922793
   PubMed Web of Science ®Google Scholar
• Kang EH, Nakashima R, Mimori T, et al. Myositis autoantibodies in Korean patients with inflammatory myositis: anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis. BMC Musculoskelet Disord. 2010;11(1):223.20875136
   PubMed Web of Science ®Google Scholar
• Betteridge Z, Gunawardena H, North J, Slinn J, McHugh N. Identification of a novel autoantibody directed against small ubiquitin-like modifier activating enzyme in dermatomyositis. Arthritis Rheum. 2007;56:3132–3137. doi:10.1002/(ISSN)1529-013117763420
   PubMed Web of Science ®Google Scholar
• Tarricone E, Ghirardello A, Rampudda M, Bassi N, Punzi L, Doria A. Anti-SAE antibodies in autoimmune myositis: identification by unlabelled protein immunoprecipitation in an Italian patient cohort. J Immunol Methods. 2012;384:128–134. doi:10.1016/j.jim.2012.07.01922884621
   PubMed Web of Science ®Google Scholar
• Muro Y, Sugiura K, Akiyama M. Low prevalence of anti-small ubiquitin-like modifier activating enzyme antibodies in dermatomyositis patients. Autoimmunity. 2013;46:279–284. doi:10.3109/08916934.2012.75595823215730
   PubMed Web of Science ®Google Scholar
• Fujimoto M, Matsushita T, Hamaguchi Y, et al. Autoantibodies to small ubiquitin-like modifier activating enzymes in Japanese patients with dermatomyositis: comparison with a UK Caucasian cohort. Ann Rheum Dis. 2013;72:151–153. doi:10.1136/annrheumdis-2012-20173622843487
   PubMed Web of Science ®Google Scholar
• Satoh M, Tanaka S, Ceribelli A, Calise SJ, Chan EKL. A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy. Clin Rev Allergy Immunol. 2017;52:1–19. doi:10.1007/s12016-015-8510-y26424665
   PubMed Web of Science ®Google Scholar
• Mahler M, Miller FW, Fritzler MJ. Idiopathic inflammatory myopathies and the anti-synthetase syndrome: a comprehensive review. Auto Immun Rev. 2014;13:367–371. doi:10.1016/j.autrev.2014.01.022
   PubMed Web of Science ®Google Scholar
• García-De La Torre I. Clinical usefulness of autoantibodies in idiopathic inflammatory myositis. Front Immunol. 2015;6:331. doi:10.3389/fimmu.2015.0033126161084
   PubMed Web of Science ®Google Scholar
• Ichimura Y, Matsushita T, Hamaguchi Y, et al. Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Ann Rheum Dis. 2012;71:710–713. doi:10.1136/annrheumdis-2011-20069722258483
   PubMed Web of Science ®Google Scholar
• Oddis F, GOEL O, Goel E, et al. Clinical and serological characterization of the anti-MJ antibody in childhood myositisz. Arthritis Rheum. 1997;40:139. doi:10.1002/1529-0131(199707)40:7<1267::AID-ART11>3.0.CO;2-L
   Web of Science ®Google Scholar
• Rogers A, Chung L, Li S, Casciola-Rosen L, Fiorentino DF. Cutaneous and systemic findings associated with nuclear matrix Protein 2 antibodies in adult dermatomyositis patients. Arthritis Care Res. 2017;69:1909–1914. doi:10.1002/acr.v69.12
   PubMed Web of Science ®Google Scholar
• Ceribelli A, Fredi M, Taraborelli M, et al. Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/dermatomyositis. Arthritis Res Ther. 2012;14(2):R97.22546500
   PubMed Web of Science ®Google Scholar
• Butt Z, Patel L, Das MK, Mecoli CA, Ramji A. NXP-2 positive dermatomyositis: a unique clinical presentation. Case Rep Rheumatol. 2017;2017:1–4. doi:10.1155/2017/4817275
   Google Scholar
• Espada G, Maldonado Cocco JA, Fertig N, Oddis CV. Clinical and serologic characterization of an Argentine pediatric myositis cohort: identification of a novel autoantibody (anti-MJ) to a 142-kDa protein. J Rheumatol. 2009;36:2547–2551. doi:10.3899/jrheum.09046119833756
   PubMed Web of Science ®Google Scholar
• Pau-Charles I, Moreno PJ, Ortiz-Ibáñez K, et al. Anti-MDA5 positive clinically amyopathic dermatomyositis presenting with severe cardiomyopathy. J Eur Acad Dermatol Venereol. 2014;28:1097–1102. doi:10.1111/jdv.1230025243267
   PubMed Web of Science ®Google Scholar
• Sato S, Kuwana M, Fujita T, Suzuki Y. Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease. Mod Rheumatol. 2013;23:496–502. doi:10.3109/s10165-012-0663-422644102
   PubMed Web of Science ®Google Scholar
• Gunawardena H, Betteridge ZE, McHugh NJ. Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. Rheumatology. 2009;48:607–612. doi:10.1093/rheumatology/kep07819439503
   PubMed Web of Science ®Google Scholar
• Euwer RL, Sontheimer RD. Amyopathic dermatomyositis (dermatomyositis siné myositis): presentation of six new cases and review of the literature. J Am Acad Dermatol. 1991;24:959–966. doi:10.1016/0190-9622(91)70153-S1869684
   PubMed Web of Science ®Google Scholar
• Chaisson NF, Paik J, Orbai AM, et al. A novel dermato-pulmonary syndrome associated with MDA-5 antibodies: report of 2 cases and review of the literature. Medicine (United States). 2012;96. doi:10.1094/PDIS-11-11-0999-PDN
   Google Scholar
• Dupont S, Mamidi A, Cordenonsi M, et al. FAM/USP9x, a deubiquitinating enzyme essential for TGFbeta signaling, controls Smad4 monoubiquitination. Cell. 2009;136:123–135. doi:10.1016/j.cell.2008.10.05119135894
   PubMed Web of Science ®Google Scholar
• Dupont S, Zacchigna L, Cordenonsi M, et al. Germ-layer specification and control of cell growth by Ectodermin, a Smad4 ubiquitin ligase. Cell. 2005;121:87–99. doi:10.1016/j.cell.2005.01.03315820681
   PubMed Web of Science ®Google Scholar
• Siegel PM, Massagué J. Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer. Nat Rev Cancer. 2003;3:807–820. doi:10.1038/nrc120814557817
   PubMed Web of Science ®Google Scholar
• Masiak A, Kulczycka J, Czuszyńska Z, Zdrojewski Z. Clinical characteristics of patients with anti-TIF1-γ antibodies. Reumatologia. 2016;1:14–18. doi:10.5114/reum.2016.58756
   Google Scholar
• Hoshino K, Muro Y, Sugiura K, Tomita Y, Nakashima R, Mimori T. Anti-MDA5 and anti-TIF1-γ antibodies have clinical significance for patients with dermatomyositis. Rheumatology. 2010;49:1726–1733. doi:10.1093/rheumatology/keq15320501546
   PubMed Web of Science ®Google Scholar